Prognostic value of pre-operative serum uric acid levels in esophageal squamous cell carcinoma patients who undergo R0 esophagectomy

Cancer Biomarkers

Volumn 17, Issue 1, 2016, Pages 89-96

  Chen, You Fang ^a   Li, Qiang ^a   Chen, Dong Tai ^a   Pan, Jia Hao ^a   Chen, Yong Hua ^a   Wen, Zhe Sheng ^a   Zeng, Wei An ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

disease free survival; Esophageal squamous cell carcinoma; overall survival; prognostic factor; SUA

Indexed keywords

URIC ACID; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEDICAL RECORD REVIEW; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR DIFFERENTIATION; URIC ACID BLOOD LEVEL; BLOOD; CANCER GRADING; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PREOPERATIVE PERIOD; PROGNOSIS; ROC CURVE; URIC ACID;

EID: 84978542825     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-160621     Document Type: Article

References (37)

1. J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman, and F. Bray. Cancer incidence, and mortality worldwide: sources, methods, and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359-86.
2. M. Arnold, I. Soerjomataram, J. Ferlay, and D. Forman, Global incidence of oesophageal cancer by histological subtype in 2012. Gut 64 (2015), 381-7.
3. Y. Lin, Y. Totsuka, Y. He, S. Kikuchi, Y. Qiao, J. Ueda, W. Wei, M. Inoue, and H. Tanaka, Epidemiology of esophageal cancer in Japan, and China. J Epidemiol 23 (2013), 233-42.
4. P. Guo, and K. Li, Trends in esophageal cancer mortality in China during 1987-2009: age, period, and birth cohort analyzes. Cancer Epidemiol 36 (2012), 99-105.
5. P.C. Enzinger, and R.J. Mayer, Esophageal cancer. N Engl J Med 349 (2003), 2241-52.
6. X.H. Li, X.P. Wang, W.S. Gu, J.H. Lin, H. Huang, T. Kang, L. Zhang, H. Chen, and X. Zheng, Clinical Significance of Preoperative Thrombin Time in Patients with Esophageal Squamous Cell Carcinoma following Surgical Resection. PLoS ONE 10 (2015), e0140323.
7. J. Qin, S.G. Wu, J.Y. Sun, H.X. Lin, Z.Y.He andQ. Li, Effect of blood type on survival of Chinese patients with esophageal squamous cell carcinoma. Onco Targets Ther 8 (2015), 947-53.
8. M.A. Fini, A. Elias, R.J. Johnson, and R.M. Wright, Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med 1 (2012), 16.
9. S. Yan, P. Zhang, W. Xu, Y. Liu, B. Wang, T. Jiang, C. Hua, X. Wang, D. Xu, and B. Sun, Serum Uric Acid Increases Risk of Cancer Incidence, and Mortality: A Systematic Review, and Meta-Analysis. Mediators Inflamm 2015 (2015), 764250.
10. T. Dziaman, Z. Banaszkiewicz, K. Roszkowski, D. Gackowski, E. Wisniewska, R. Rozalski, M. Foksinski, A. Siomek, E. Speina, A. Winczura, A. Marszalek, B. Tudek, and R. Olinski, 8-Oxo-7, 8-dihydroguanine, and uric acid as efficient predictors of survival in colon cancer patients. Int J Cancer 134 (2014), 376-83.
11. H. Lin, H.X. Lin, N. Ge, H.Z. Wang, R. Sun, and W.H. Hu, Plasma uric acid, and tumor volume are highly predictive of outcome in nasopharyngeal carcinoma patients receiving intensity modulated radiotherapy. Radiat Oncol 8 (2013), 121.
12. M. Heinig, and R.J. Johnson, Role of uric acid in hypertension, renal disease, and metabolic syndrome. Cleve Clin J Med 73 (2006), 1059-64.
13. M. Stotz, J. Szkandera, J. Seidel, T. Stojakovic, H. Samonigg, D. Reitz, T. Gary, P. Kornprat, R. Schaberl-Moser, G. Hoefler, A. Gerger, and M. Pichler, Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients. PLoS ONE 9 (2014), e104730.
14. O. Tanriverdi, S. Cokmert, E. Oktay, K.N. Pilanci, S. Menekse, M. Kocar, C.A. Sen, N. Avci, T. Akman, C. Ordu, G. Goksel, and N. Meydan, Prognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy: a study of the Turkish Descriptive Oncological Researches Group. Med Oncol 31 (2014), 217.
15. J.Y. Yin, Q. Tang, L.L. Zhai, L.Y. Zhou, J. Qian, J. Lin, X.M. Wen, J.D. Zhou, Y.Y. Zhang, X.W. Zhu, and Z.Q. Deng, High expression of OCT4 is frequent, and may cause undesirable treatment outcomes in patients with acute myeloid leukemia. Tumour Biol (2015
16. L.J. Horsfall, I. Nazareth, and I. Petersen, Serum uric acid, and the risk of respiratory disease: a population-based cohort study. Thorax 69 (2014), 1021-6.
17. E. Lickl, G. Alth, R. Ebermann, R.H. Beck, and K. Tuma, Serum urate level, and cancer. Med Hypotheses 28 (1989), 193-5.
18. A.M. Strasak, S. Lang, T. Kneib, L.J. Brant, J. Klenk, W. Hilbe, W. Oberaigner, E. Ruttmann, L. Kaltenbach, H. Concin, G. Diem, K.P. Pfeiffer, H. Ulmer, Vhm, and P.P.S. Group, Use of penalized splines in extended Cox-Type additive hazard regression to flexibly estimate the effect of timevarying serum uric acid on risk of cancer incidence: a prospective, population-based study in 78, 850 men. Ann Epidemiol 19 (2009), 15-24.
19. H. Demir, Z.A. Akkus, A. Cebi, T. Cakir, and M. Izmirli, Catalase, carbonic anhydrase, and other biochemical parameters in esophageal cancers in Turkey. Asian Pac J Cancer Prev 11 (2010), 1029-32.
20. J.M. Fernandez-Real, and J.C. Pickup, Innate immunity, insulin resistance, and type 2 diabetes. Trends Endocrinol Metab 19 (2008), 10-6.
21. A.M. Lorincz, and S. Sukumar, Molecular links between obesity, and breast cancer. Endocr Relat Cancer 13 (2006), 279-92.
22. Y. Shi, J.E. Evans, and K.L. Rock, Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425 (2003), 516-21.
23. Y. Shi, W. Zheng, and K.L. Rock. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci U S A 97 (2000), 14590-5.
24. A.L. Jackson, and L.A. Loeb, The contribution of endogenous sources of DNA damage to the multiple mutations in cancer, Mutat Res 477 (2001), 7-21.
25. P. Storz, Reactive oxygen species in tumor progression, Front Biosci 10 (2005), 1881-96.
26. L.M. Coussens, and Z. Werb, Inflammation, and cancer. Nature 420 (2002), 860-7.
27. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, Cancerrelated inflammation. Nature 454 (2008), 436-44.
28. J.B. Lam, K.H. Chow, A. Xu, K.S. Lam, J. Liu, N.S. Wong, R.T. Moon, P.R. Shepherd, G.J. Cooper, and Y. Wang, Adiponectin haploinsufficiency promotes mammary tumor development in MMTV-PyVT mice by modulation of phosphatase, and tensin homolog activities. PLoS ONE 4 (2009), e4968.
29. T. Lyngdoh, P. Marques-Vidal, F. Paccaud, M. Preisig, G. Waeber, M. Bochud, and P. Vollenweider, Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. PLoS ONE 6 (2011), e19901.
30. K. Saito, and K. Kihara, Role of C-reactive protein as a biomarker for renal cell carcinoma. Expert Rev Anticancer Ther 10 (2010), 1979-89.
31. C. Siemes, L.E. Visser, J.W. Coebergh, T.A. Splinter, J.C. Witteman, A.G. Uitterlinden, A. Hofman, H.A. Pols, and B.H. Stricker, C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 24 (2006), 5216-22.
32. K.K. Tsilidis, C. Branchini, E. Guallar, K.J. Helzlsouer, T.P. Erlinger, and E.A. Platz, C-reactive protein, and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 123 (2008), 1133-40.
33. N. Linder, C. Haglund, M. Lundin, S. Nordling, A. Ristimaki, A. Kokkola, J. Mrena, J.P. Wiksten, and J. Lundin, Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer. J Clin Pathol 59 (2006), 965-71.
34. N. Linder, J. Lundin, J. Isola, M. Lundin, K.O. Raivio, and H. Joensuu, Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer. Clin Cancer Res 11 (2005), 4372-81.
35. M.A. Fini, J. Monks, S.M. Farabaugh, and R.M. Wright, Contribution of xanthine oxidoreductase to mammary epithelial, and breast cancer cell differentiation in part modulates inhibitor of differentiation-1. Mol Cancer Res 9 (2011), 1242-54.
36. H.S. Shin, H.R. Lee, D.C. Lee, J.Y. Shim, K.H. Cho, and S.Y. Suh, Uric acid as a prognostic factor for survival time: a prospective cohort study of terminally ill cancer patients. J Pain Symptom Manage 31 (2006), 493-501.
37. R. Dhankhar, K. Dahiya, T.K. Sharma, V.S. Ghalaut, R. Atri, and V. Kaushal, Diagnostic significance of adenosine deaminase, uric acid, and C-reactive protein levels in patients of head, and neck carcinoma. Clin Lab 57 (2011), 795-8.